Prosecution Insights
Last updated: August 15, 2026

Codexis Inc.

9 pending office actions • 4 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
7
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (22%)
3
Medium (33%)
3
Easy (33%)
1
Unknown (11%)

Rejection Statute Mix

BucketCases
§103 only1 (11%)
§112 only2 (22%)
Double-patenting only1 (11%)
Double-patenting + other2 (22%)
Multi-statute (no §101)2 (22%)
No statute on record1 (11%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
78% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
2
Business / Other
22% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HOLLAND, PAUL J 1 57.3% +64.7%
MEAH, MOHAMMAD Y 1 70.9% +42.6%
HUTSON, RICHARD G 1 65.0% +52.9%
ROBINSON, HOPE A 1 67.6% +43.3%
GRAY, JESSICA 1 0.0% +0.0%
MCKNIGHT, CIARA A 1 59.2% +38.1%
FRONDA, CHRISTIAN L 1 82.6% +14.0%
STEADMAN, DAVID J 1 57.7% +29.5%
LU, FRANK WEI MIN 1 62.6% +67.6%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18516054 P450-BM3 VARIANTS WITH IMPROVED ACTIVITY MCKNIGHT, CIARA A 34d
18181760 ENGINEERED MONOAMINE OXIDASES FOR THE PREPARATION OF STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS STEADMAN, DAVID J 72d
18395294 ENGINEERED RNA LIGASE VARIANTS GRAY, JESSICA

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18046893 RECOMBINANT REVERSE TRANSCRIPTASE VARIANTS LU, FRANK WEI MIN 51d overdue
18247054 ENGINEERED PANTOTHENATE KINASE VARIANT ENZYMES FRONDA, CHRISTIAN L 4d overdue
18516054 P450-BM3 VARIANTS WITH IMPROVED ACTIVITY MCKNIGHT, CIARA A 34d
18181760 ENGINEERED MONOAMINE OXIDASES FOR THE PREPARATION OF STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS STEADMAN, DAVID J 72d
18822990 ENGINEERED PANTOTHENATE KINASE VARIANT ENZYMES HOLLAND, PAUL J
18781007 LOV-D ACYLTRANSFERASE MEDIATED ACYLATION MEAH, MOHAMMAD Y
18661523 ENGINEERED RNA POLYMERASE VARIANTS HUTSON, RICHARD G
18638060 ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS ROBINSON, HOPE A

Top Art Units

Art UnitApps
1652 3
1656 2
1682 1
1683 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18822990 ENGINEERED PANTOTHENATE KINASE VARIANT ENZYMES HOLLAND, PAUL J §112DP Non-Final OA Pending Sep 03, 2024
18781007 LOV-D ACYLTRANSFERASE MEDIATED ACYLATION MEAH, MOHAMMAD Y DP Non-Final OA Pending Jul 23, 2024
18661523 ENGINEERED RNA POLYMERASE VARIANTS HUTSON, RICHARD G 1652 §103 Non-Final OA Pending May 10, 2024
18638060 ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS ROBINSON, HOPE A 1652 §112 Non-Final OA Pending Apr 17, 2024
18395294 ENGINEERED RNA LIGASE VARIANTS GRAY, JESSICA 1682 §102§103DP Non-Final OA Pending Dec 22, 2023
18516054 P450-BM3 VARIANTS WITH IMPROVED ACTIVITY MCKNIGHT, CIARA A 1656 §102§103Other Non-Final OA 34d Pending Nov 21, 2023
18247054 ENGINEERED PANTOTHENATE KINASE VARIANT ENZYMES FRONDA, CHRISTIAN L 1652 Other Final Rejection 4d overdue Pending Mar 28, 2023
18181760 ENGINEERED MONOAMINE OXIDASES FOR THE PREPARATION OF STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS STEADMAN, DAVID J 1656 §102§103§112 Non-Final OA 72d Pending Mar 10, 2023
18046893 RECOMBINANT REVERSE TRANSCRIPTASE VARIANTS LU, FRANK WEI MIN 1683 §112 Final Rejection 51d overdue Pending Oct 14, 2022

Managing Codexis Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month